search
Back to results

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Primary Purpose

Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL)

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
KT-333
Sponsored by
Kymera Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non Hodgkin Lymphoma (NHL)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Phase 1a Only: Histologically or pathologically confirmed Lymphomas (including Hodgkin's, B-cell, T-cell, Small Lymphocytic, or NK-cell Lymphomas and LGL-L) and solid tumors with the exception of chronic lymphocytic leukemia (CLL) Note: Patients with indolent NHL and small lymphocytic lymphoma (SLL) are only eligible if not require immediate cytoreductive therapy or if there are no available treatments with potential benefit.
  2. Phase 1b Only: Histologically or pathologically confirmed PTCL, CTCL, LGL-L [T-cell LGL-L or Chronic Lymphoproliferative Disorder of NK-cells (CLPD-NK)], or solid tumors.
  3. Fresh or archival formalin fixed paraffin embedded (FFPE) tumor tissue or 15 slides preferably collected within 6 months or 2 years prior to first dose of the study drug (for lymphoma and solid tumor patients respectively).
  4. Phase 1a only: Lymphoma and Solid Tumor: Relapsed and/or refractory disease to at least 2 prior systemic standard of care treatments or for whom standard therapies are not available.
  5. Phase 1a: LGL-L: Relapsed and/or refractory disease to at least 1 prior systemic standard of care treatment or for whom standard therapies are not available.
  6. Phase 1b only: All disease types: Relapsed and/or refractory disease to at least 1 prior systemic standard of care treatments or for whom standard therapies are not available.
  7. LGL-L patients only (hematology specific criteria):

    • One of the following:

      • Severe neutropenia < 500/mm3, or,
      • Symptomatic anemia and/or,
      • Transfusion-dependent anemia.
    • ANC ≥ 200/μL at Screening and C1D1 (pre dose)
    • Platelet count ≥ 100,000/μL (assessed ≥ 7 days following last platelet transfusion in patients with thrombocytopenia requiring platelets).
  8. LGL-L Patients Only (baseline disease characteristics):

    • CD3+CD8+ cell population >650/mm3;
    • CD3+CD8+CD57+ population >500/mm3;
    • Presence of a clonal T-cell receptor (within 1 month of diagnosis);
    • Note: patients with T-LGLL may be included with PI approval even if CD3+CD8+ cell population is<650/mm3 or CD3+CD8+CD57+ population is <500/mm3, though +TCR is required;
    • Natural-Killer (NK) LGL is also permitted, provided there is a clonal NK-cell population noted with>500 cells/mm3
  9. PTCL and solid tumors Only: Measurable disease at Screening. Solid tumor patients with non-measurable disease are allowed in Phase1a
  10. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening and C1D1 (pre-dose).
  11. Adequate bone marrow function at Screening and C1D1 (pre-dose) for all patients except those with LGL-L Adequate liver/kidney organ function at Screening and C1D1 (pre-dose) for all patients. Women of childbearing potential (WOCBP) must agree to use highly effective contraceptive methods for the duration of study treatment and 6 months after the last dose of KT333.

Exclusion Criteria:

  1. History or suspicion of central nervous system (CNS) metastases.
  2. Diagnosis of Chronic Lymphocytic Leukemia (CLL).
  3. History of or active concurrent malignancy other than lymphoma or solid tumors unless the patient has been disease-free for ≥ 2 years.
  4. Patient has not recovered from any clinically significant adverse events (AEs) of previous treatments to pretreatment baseline or Grade 1 prior to first dose of study drug.
  5. Ongoing unstable cardiovascular function.
  6. Autologous hematopoietic stem cell transplant less than 3 months prior to first dose of study drug.
  7. Prior allogenic hematopoietic or bone marrow transplant.

Sites / Locations

  • UC Irvine Health-Chao Family Comprehensive Cancer CenterRecruiting
  • Norton Cancer InstituteRecruiting
  • Henry Ford HospitalRecruiting
  • Hackensack University Medical Center, John Theurer Cancer CenterRecruiting
  • Montefiore Medical Center, The University Hospital for Albert Einstein College of MedicineRecruiting
  • The Christ Hospital Cancer CenterRecruiting
  • Ohio State University Wexner Medical CenterRecruiting
  • Abramson Cancer Center of the University of Pennsylvania Perelman Center for Advanced MedicineRecruiting
  • Thomas Jefferson University, Sidney Kimmel Cancer CenterRecruiting
  • Rhode Island HospitalRecruiting
  • MD Anderson Cancer CenterRecruiting
  • University of Virginia, Emily Couric Cancer CenterRecruiting
  • University of WA/Seattle Cancer Care AllianceRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Phase 1a Dose Escalation Lymphomas

Phase 1a Dose Escalation Solid Tumors

Phase 1b Dose Expansion PTCL

Phase 1b Dose Expansion CTCL

Phase 1b Dose Expansion LGL-L

Phase 1b Dose Expansion Solid Tumor

Phase 1a Dose Escalation LGL-L

Phase 1a Dose Escalation T-PLL

Arm Description

KT-333 dosed IV weekly in 28 day cycles

KT-333 dosed IV weekly in 28 day cycles

KT-333 dosed IV weekly in 28 day cycles

KT-333 dosed IV weekly in 28 day cycles

KT-333 dosed IV weekly in 28 day cycles

KT-333 dosed IV weekly in 28 day cycles

KT-333 dosed IV weekly in 28 day cycles

KT-333 dosed IV weekly in 28 day cycles

Outcomes

Primary Outcome Measures

Safety
Incidence and severity of adverse events as assessed by CTCAE v5.0 Phase 1a/1b
Safety
Incidence and severity of clinical laboratory abnormalities in Serum Chemistry, Hematology, Coagulation Parameters and urinalysis tests as assessed by CTCAE v5.0 Phase 1a/1b
Safety
Changes in the ECG parameters, including heart rate and measures PR, QRS, QT, and QTc intervals as assessed by CTCAE v5.0 Phase 1a/1b
Maximum Tolerated Dose (MTD)
To establish the Maximum Tolerated Dose (MTD) Phase 1a
Dose Limiting Toxicities (DLTs)
Number of Participants with protocol specified Dose Limiting Toxicities (DLTs) Phase 1a

Secondary Outcome Measures

Area under the plasma concentration versus time curve for KT-333
Area under the plasma concentration versus time curve for KT-333 from time to zero to last quantifiable time point (AUC 0-t ) Phase 1a/1b
Maximum Plasma Concentration of KT-333 (Cmax)
Maximum Plasma Concentration of KT-333 (Cmax)
Time of maximum plasma concentration of KT-333 (Tmax)
Time of maximum plasma concentration of KT-333 (Tmax) Phase 1a/1b
Half-life of KT-333 if data permits (T1/2)
Half-life of KT-333 if data permits (T1/2) Phase 1a/1b
Amount of KT-333 dose excreted in urine from time zero to last collected time point (Ae0-t)
Amount of KT-333 dose excreted in urine from time zero to last collected time point (Ae0-t) Phase 1a
Evidence of clinical activity of KT-333
Evidence of clinical activity of KT-333 as determined by Objective Response Rate (ORR) as per Lugano criteria 2014 for Lymphomas Phase 1a/1b.
Evidence of clinical activity of KT-333
Evidence of clinical activity of KT-333 as determined by RECIST 1.1 to determine ORR , complete response (CR), partial response (PR) for solid tumors Phase 1a/1b.
Evidence of clinical activity of KT-333
Evidence of clinical activity of KT-333 as determined by ORR by Modified Severity-Weighted Assessment Tool (mSWAT) for Cutaneous T-Cell Lymphoma (CTCL) Phase 1a/1b
Evidence of clinical activity of KT-333
Evidence of clinical activity of KT-333 as determined by ORR by investigator assessment for Large Granular Lymphocytic Leukemia (LGL-L) Phase 1a/1b
Evidence of clinical activity of KT-333
Evidence of clinical activity of KT-333 as determined by ORR based on T-PLL International Study Group criteria, Phase 1a
Duration of Response (DOR)
Duration of Response (DOR) Phase 1a/1b

Full Information

First Posted
December 16, 2021
Last Updated
August 2, 2023
Sponsor
Kymera Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05225584
Brief Title
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Official Title
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients With Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 19, 2022 (Actual)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kymera Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L), T-cell prolymphocytic leukemia (T-PLL), and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), LGL-L, and solid tumors.
Detailed Description
This is an open-label Phase 1a (dose escalation)/1b (dose expansion) first-in-human study of KT-333 in adult patients. Patients with relapsed/refractory (R/R) lymphomas, LGL-L, T-PLL, and solid tumors will be enrolled in Phase 1a. Phase 1b will consist of separate cohorts of patients with R/R PTCL, CTCL, LGL-L, and solid tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phase 1a Dose Escalation Lymphomas
Arm Type
Experimental
Arm Description
KT-333 dosed IV weekly in 28 day cycles
Arm Title
Phase 1a Dose Escalation Solid Tumors
Arm Type
Experimental
Arm Description
KT-333 dosed IV weekly in 28 day cycles
Arm Title
Phase 1b Dose Expansion PTCL
Arm Type
Experimental
Arm Description
KT-333 dosed IV weekly in 28 day cycles
Arm Title
Phase 1b Dose Expansion CTCL
Arm Type
Experimental
Arm Description
KT-333 dosed IV weekly in 28 day cycles
Arm Title
Phase 1b Dose Expansion LGL-L
Arm Type
Experimental
Arm Description
KT-333 dosed IV weekly in 28 day cycles
Arm Title
Phase 1b Dose Expansion Solid Tumor
Arm Type
Experimental
Arm Description
KT-333 dosed IV weekly in 28 day cycles
Arm Title
Phase 1a Dose Escalation LGL-L
Arm Type
Experimental
Arm Description
KT-333 dosed IV weekly in 28 day cycles
Arm Title
Phase 1a Dose Escalation T-PLL
Arm Type
Experimental
Arm Description
KT-333 dosed IV weekly in 28 day cycles
Intervention Type
Drug
Intervention Name(s)
KT-333
Intervention Description
KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.
Primary Outcome Measure Information:
Title
Safety
Description
Incidence and severity of adverse events as assessed by CTCAE v5.0 Phase 1a/1b
Time Frame
Safety will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy
Title
Safety
Description
Incidence and severity of clinical laboratory abnormalities in Serum Chemistry, Hematology, Coagulation Parameters and urinalysis tests as assessed by CTCAE v5.0 Phase 1a/1b
Time Frame
Safety will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy
Title
Safety
Description
Changes in the ECG parameters, including heart rate and measures PR, QRS, QT, and QTc intervals as assessed by CTCAE v5.0 Phase 1a/1b
Time Frame
Safety will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy
Title
Maximum Tolerated Dose (MTD)
Description
To establish the Maximum Tolerated Dose (MTD) Phase 1a
Time Frame
Within the first 28 days of treatment
Title
Dose Limiting Toxicities (DLTs)
Description
Number of Participants with protocol specified Dose Limiting Toxicities (DLTs) Phase 1a
Time Frame
Within the first 28days of treatment
Secondary Outcome Measure Information:
Title
Area under the plasma concentration versus time curve for KT-333
Description
Area under the plasma concentration versus time curve for KT-333 from time to zero to last quantifiable time point (AUC 0-t ) Phase 1a/1b
Time Frame
Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)
Title
Maximum Plasma Concentration of KT-333 (Cmax)
Description
Maximum Plasma Concentration of KT-333 (Cmax)
Time Frame
Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)
Title
Time of maximum plasma concentration of KT-333 (Tmax)
Description
Time of maximum plasma concentration of KT-333 (Tmax) Phase 1a/1b
Time Frame
Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)
Title
Half-life of KT-333 if data permits (T1/2)
Description
Half-life of KT-333 if data permits (T1/2) Phase 1a/1b
Time Frame
Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)
Title
Amount of KT-333 dose excreted in urine from time zero to last collected time point (Ae0-t)
Description
Amount of KT-333 dose excreted in urine from time zero to last collected time point (Ae0-t) Phase 1a
Time Frame
Urine samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)
Title
Evidence of clinical activity of KT-333
Description
Evidence of clinical activity of KT-333 as determined by Objective Response Rate (ORR) as per Lugano criteria 2014 for Lymphomas Phase 1a/1b.
Time Frame
From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months
Title
Evidence of clinical activity of KT-333
Description
Evidence of clinical activity of KT-333 as determined by RECIST 1.1 to determine ORR , complete response (CR), partial response (PR) for solid tumors Phase 1a/1b.
Time Frame
From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months
Title
Evidence of clinical activity of KT-333
Description
Evidence of clinical activity of KT-333 as determined by ORR by Modified Severity-Weighted Assessment Tool (mSWAT) for Cutaneous T-Cell Lymphoma (CTCL) Phase 1a/1b
Time Frame
Composite assessment from date of baseline assessment until the date of first documented progression or date of death from any cause, whichever came first, about 18 months
Title
Evidence of clinical activity of KT-333
Description
Evidence of clinical activity of KT-333 as determined by ORR by investigator assessment for Large Granular Lymphocytic Leukemia (LGL-L) Phase 1a/1b
Time Frame
From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months
Title
Evidence of clinical activity of KT-333
Description
Evidence of clinical activity of KT-333 as determined by ORR based on T-PLL International Study Group criteria, Phase 1a
Time Frame
From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months
Title
Duration of Response (DOR)
Description
Duration of Response (DOR) Phase 1a/1b
Time Frame
From date of first of response to the date of documented first progression or death whichever comes first, about 18 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Phase 1a Only: Cytologically or pathologically confirmed Lymphomas (including Hodgkin's, B-cell, T-cell, Small Lymphocytic, or Natural-Killer (NK)-cell Lymphomas and LGL-L), T-PLL and solid tumors with the exception of chronic lymphocytic leukemia (CLL) Note: Patients with indolent non-Hodgkin's lymphoma (NHL) and small lymphocytic lymphoma (SLL) are only eligible if not require immediate cytoreductive therapy or if there are no available treatments with potential benefit. Phase 1b Only: Histologically or pathologically confirmed PTCL, CTCL, LGL-L [T-cell LGL-L or Chronic Lymphoproliferative Disorder of NK-cells (CLPD-NK)], or solid tumors. Fresh or archival formalin fixed paraffin embedded (FFPE) tumor tissue or 15 slides preferably collected within 6 months or 2 years prior to first dose of the study drug (for lymphoma and solid tumor patients respectively). Phase 1a only: Lymphoma and Solid Tumor: Relapsed and/or refractory disease to at least 2 prior systemic standard of care treatments or for whom standard therapies are not available. Phase 1a: LGL-L/T-PLL only: Relapsed and/or refractory disease to at least 1 prior systemic standard of care treatment or for whom standard therapies are not available. Phase 1b only: All disease types: Relapsed and/or refractory disease to at least 1 prior systemic standard of care treatments or for whom standard therapies are not available. LGL-L patients only (hematology specific criteria): One of the following: Severe neutropenia < 500/mm3, or, Symptomatic anemia and/or, Transfusion-dependent anemia. ANC ≥ 200/μL at Screening and C1D1 (pre dose) Platelet count ≥ 100,000/μL (assessed ≥ 7 days following last platelet transfusion in patients with thrombocytopenia requiring platelets). LGL-L Patients Only (baseline disease characteristics): CD3+CD8+ cell population >650/mm3; CD3+CD8+CD57+ population >500/mm3; Presence of a clonal T-cell receptor (within 1 month of diagnosis); Note: patients with T-LGLL may be included with PI approval even if CD3+CD8+ cell population is<650/mm3 or CD3+CD8+CD57+ population is <500/mm3, though +TCR is required; NK LGL is also permitted, provided there is a clonal NK-cell population noted with>500 cells/mm3 PTCL and solid tumors Only: Measurable disease at Screening. Solid tumor patients with non-measurable disease are allowed in Phase1a T-PLL: Measurable disease per Lugano and/or atypical T lymphocytes quantifiable by flow cytometry or morphology in the peripheral blood or bone marrow. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening and C1D1 (pre-dose). Adequate bone marrow function at Screening and C1D1 (pre-dose) for all patients except those with LGL-L Adequate liver/kidney organ function at Screening and C1D1 (pre-dose) for all patients. Women of childbearing potential (WOCBP) must agree to use highly effective contraceptive methods for the duration of study treatment and 6 months after the last dose of KT333. Exclusion Criteria: Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Note: Patients with solid tumors are eligible if their CNS metastases or cord compression have been treated (e.g., radiotherapy, stereotactic surgery) and they are clinically stable, off steroids for at least 4 weeks before first dose of study drug and have no evidence of progression at time of study enrollment. Note: Patients with lymphomas are eligible if their CNS metastases or cord compression have been treated effectively (i.e. achieved CR) and there is no clinical or radiographic evidence of active lymphoma. Diagnosis of Chronic Lymphocytic Leukemia (CLL). History of or active concurrent malignancy other than lymphoma or solid tumors unless the patient has been disease-free for ≥ 2 years. Patient has not recovered from any clinically significant adverse events (AEs) of previous treatments to pretreatment baseline or Grade 1 prior to first dose of study drug. Ongoing unstable cardiovascular function. Autologous hematopoietic stem cell transplant less than 3 months prior to first dose of study drug. Prior allogenic hematopoietic or bone marrow transplant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ashwin Gollerkeri, MD
Organizational Affiliation
Kymera Therapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
UC Irvine Health-Chao Family Comprehensive Cancer Center
City
Orange
State/Province
California
ZIP/Postal Code
92868-3201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lauren Pinter Brown, MD
Phone
877-827-8839
Email
ucstudy@hs.uci.edu
Facility Name
Norton Cancer Institute
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dana Haycraft
Phone
502-899-3366
Email
dana.haycraft@nortonhealthcare.org
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cesar Figueras, MBA, HRM, BSN, RN
Phone
313-556-8731
Email
cfiguer1@hfhs.org
Facility Name
Hackensack University Medical Center, John Theurer Cancer Center
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth McCarthy, MSN, RN
Phone
412-860-6447
Email
elizabethl.mccarthy@hmhn.org
Facility Name
Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joel Victor
Phone
718-920-6680
Email
jovictor@montefiore.org
Facility Name
The Christ Hospital Cancer Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abby Reed
Phone
513-585-1140
Email
abby.reed@thechristhospital.com
Facility Name
Ohio State University Wexner Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210-1240
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lily Yang
Phone
614-293-6191
Email
lily.yang@osumc.edu
First Name & Middle Initial & Last Name & Degree
John Reneau, MD,PhD
Facility Name
Abramson Cancer Center of the University of Pennsylvania Perelman Center for Advanced Medicine
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heather Yost
Phone
267-582-3238
Email
Yost@pennmedicine.upenn.edu
Facility Name
Thomas Jefferson University, Sidney Kimmel Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierluigi Porcu, MD
Phone
215-586-0199
Email
askphase1@jefferson.edu
Facility Name
Rhode Island Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Schumacher
Phone
401-444-3234
Email
aschumacher@lifespan.org
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Auris Huen, MD
Phone
713-745-1113
Email
aohuen@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Oluwakemi Awolowo
Phone
713-745-1414
Email
ORAwolowo@mdanderson.org
Facility Name
University of Virginia, Emily Couric Cancer Center
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mark Dewey
Phone
434-243-0425
Email
UVACANCERTRIALS@uvahealth.org
First Name & Middle Initial & Last Name & Degree
Enrica Marchi, MD
Facility Name
University of WA/Seattle Cancer Care Alliance
City
Seattle
State/Province
Washington
ZIP/Postal Code
98195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen Smith, MD
Phone
206-606-6546
Email
ssmith50@seattlecca.org

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

We'll reach out to this number within 24 hrs